Import from "@/components/mdx"

Armour Thyroid vs Tirosint: Why Some Women Take Both, and What the Evidence Says

What Each Drug Actually Is

Armour Thyroid and Tirosint solve different problems, and understanding what each one is made of explains why some clinicians reach for both.

Armour Thyroid is a natural desiccated thyroid (NDT) extract derived from porcine (pig) thyroid glands. Each grain (65 mg) contains approximately 38 mcg of levothyroxine (T4) and 9 mcg of liothyronine (T3). That fixed 4.22:1 ratio of T4 to T3 is set by the animal's biology, not by a pharmacist, which is both its appeal and its limitation. You get pre-formed T3 without relying on your own conversion enzymes. The downside is that you cannot adjust T3 independently of T4.

Tirosint is a brand of levothyroxine delivered in a soft-gel capsule filled with liquid. It contains levothyroxine, gelatin, glycerin, and water. No dyes. No fillers. No acacia. This stripped-down formula was designed specifically for women and men whose stomachs, medications, or GI conditions interfere with absorbing standard levothyroxine tablets.

Why absorption matters more than most people realize

Standard levothyroxine tablets are notoriously sensitive to food, coffee, calcium, iron, proton-pump inhibitors, and bile-acid sequestrants. Tirosint's liquid-filled capsule bypasses most of that interference. In a direct-comparison study by Vita et al. (2014), patients with autoimmune thyroiditis who switched from standard levothyroxine tablets to Tirosint gel-caps achieved better TSH control and needed lower doses, suggesting meaningfully superior absorption.

The T3 conversion problem in women

Your thyroid gland produces mostly T4, a storage hormone your cells convert to active T3. Several conditions common in women, including Hashimoto's thyroiditis, PCOS-related insulin resistance, chronic caloric restriction, and elevated estrogen states, can reduce the activity of deiodinase enzymes responsible for that conversion. A woman with a DIO2 gene polymorphism may convert T4 to T3 less efficiently than average, and she may still feel fatigued, cold, or cognitively foggy even when her TSH looks perfect on levothyroxine alone. This is the physiological rationale for adding a T3 source.

The Case for Combining Armour Thyroid and Tirosint

Most clinicians prescribe one or the other. A smaller subset prescribes Tirosint as the primary T4 source and adds a low-dose of Armour Thyroid specifically for its T3 component. The logic is that Tirosint's predictable absorption provides a stable T4 baseline, while Armour's T3 fills the conversion gap without requiring a separate liothyronine (Cytomel) prescription.

Think of this as a tiered hormone strategy:

• Layer 1 (T4 base): Tirosint gel-cap, taken fasting, gives you a clean, well-absorbed levothyroxine dose unaffected by fillers, dyes, or GI interference.
• Layer 2 (T3 supplement): A half-grain or one-grain of Armour Thyroid adds roughly 4-9 mcg of T3, addressing residual symptoms without the sharp peak-and-trough that full NDT monotherapy can produce.

This approach is not a standard-of-care protocol. No large randomized trial has tested Tirosint plus Armour Thyroid as a combination against either monotherapy. What does exist is a solid body of evidence that some patients feel better on combination T4+T3 therapy, and a separate line of evidence that Tirosint outperforms standard tablets in people with absorption difficulties.

What the Hoang 2013 crossover trial actually found

The most frequently cited trial supporting NDT is Hoang et al. (J Clin Endocrinol Metab, 2013). In this randomized crossover study of 70 hypothyroid patients, participants took either desiccated thyroid extract or levothyroxine for 16 weeks each. At the end, approximately 49% preferred the NDT period, 19% preferred levothyroxine, and 33% had no preference. Patients on NDT lost a mean of 4 pounds more and reported better mood and general wellbeing scores. The trial was not large enough to be definitive, and it used Armour Thyroid against standard-tablet levothyroxine, not against Tirosint specifically, so absorption differences may have influenced the results in ways the study could not control.

Who tends to notice a difference

Women who describe persistent symptoms on optimized levothyroxine monotherapy are the most common candidates for combination discussions. Symptoms frequently described include brain fog that does not resolve when TSH normalizes, cold hands and feet despite euthyroid TSH, and fatigue that persists through the afternoon. These are non-specific, but they are disproportionately reported by women, and they do track with lower free T3 levels in some, though not all, observational data.

Sex-Specific Physiology: How Hormones Change Your Thyroid Needs

Reproductive years

During the menstrual cycle, estrogen fluctuations affect thyroid-binding globulin (TBG). Rising estrogen in the follicular phase increases TBG, binding more circulating T4 and temporarily reducing free T4. Most women with adequate thyroid reserve compensate automatically. Women on fixed levothyroxine doses may notice subtle symptom fluctuation across their cycle, though TSH rarely shifts enough to trigger a dose change.

Women with PCOS often have higher rates of thyroid autoimmunity, with Hashimoto's thyroiditis occurring in up to 26% of women with PCOS in some registry data, compared with roughly 10% in the general female population. If insulin resistance reduces T4-to-T3 conversion, a woman with PCOS and Hashimoto's may be a reasonable candidate for adding a T3 source, though this should be individualized.

Perimenopause

Perimenopause adds complexity. Estrogen fluctuates wildly rather than cycling predictably. TBG levels shift. Sleep disruption, hot flashes, palpitations, and cognitive changes overlap heavily with both hypothyroid and hyperthyroid symptoms. A woman who starts experiencing palpitations after her clinician adds Armour Thyroid during perimenopause may be reacting to Armour's T3 peak, to estrogen withdrawal, or to both. Differentiating these requires free T3 measurement and sometimes a 24-hour Holter monitor, not simply a TSH.

Post-menopause

Post-menopausal women face a specific bone-loss concern with any T3-containing therapy. Supraphysiologic T3, even transiently, accelerates bone resorption. The T3 spike after each Armour Thyroid dose is real: free T3 peaks 2-4 hours after NDT ingestion and then declines, producing a pattern the thyroid gland does not naturally create. Over years, this repeated spike may contribute to reduced bone mineral density, particularly in women who are already losing bone after menopause. If you are post-menopausal and your clinician recommends Armour Thyroid or the combination, ask for a baseline DEXA scan and a plan to repeat it at two years.

Pregnancy, Lactation, and Contraception

Pregnancy. Both T4 and T3 are essential for fetal neurological development, particularly in the first trimester before the fetal thyroid is functional. Women with hypothyroidism who become pregnant typically need a 25-30% increase in levothyroxine dose, often detectable by week 4-6 of gestation, according to ACOG Practice Bulletin guidance. Standard practice is to treat pregnant women with levothyroxine (T4 only), not NDT, because T4 crosses the placenta more steadily and you can titrate it precisely. Armour Thyroid's fixed T3 component makes fine dosing adjustment harder, and there are no adequately powered trials of NDT monotherapy or combination therapy in pregnancy.

If you are taking Armour Thyroid or the Tirosint-plus-Armour combination and you are trying to conceive, discuss transitioning to levothyroxine monotherapy, preferably Tirosint for its absorption reliability, before conception or at a confirmed positive pregnancy test. Target TSH below 2.5 mIU/L in the first trimester, per ACOG guidance.

Lactation. Levothyroxine passes into breast milk in small amounts that are physiologically normal, not pharmacologically harmful, and breastfeeding is safe on Tirosint. Armour Thyroid also transfers T4 and T3 into breast milk in amounts consistent with normal lactation physiology. Neither drug is contraindicated while breastfeeding, but your dose should be rechecked 6-12 weeks postpartum because requirements often shift again after delivery and during lactation.

Contraception. Neither Armour Thyroid nor Tirosint is a teratogen requiring mandatory contraception in the way that drugs like methotrexate or isotretinoin do. The concern is different: undertreated hypothyroidism during pregnancy carries real risks (miscarriage, preterm birth, impaired fetal neurodevelopment), so the directive is not to avoid these drugs but to ensure your thyroid function is well-controlled before and during pregnancy, and to know that NDT is not the preferred form during gestation.

Switching from Armour Thyroid to Tirosint

Some women switch in this direction, giving up NDT's T3 to gain Tirosint's absorption reliability. This might be the right move if you have Hashimoto's with fluctuating absorption, celiac disease affecting GI absorption, or if heart palpitations or bone-density concerns make the T3 in Armour Thyroid a liability.

Conversion math

A rough conversion used in clinical practice is that each grain (65 mg) of Armour Thyroid is roughly equivalent to 60-65 mcg of levothyroxine in T4-equivalent terms, though this is not a precise exchange. Because Tirosint absorbs better than standard tablets, some clinicians start at a slightly lower dose than the calculated T4 equivalent when switching, then recheck TSH and free T4 at six weeks.

What to monitor when switching

• TSH and free T4 at 6 weeks after the switch.
• Free T3 if you had persistent symptoms on levothyroxine previously and you want to know whether T3 was what was helping.
• Symptom diary for the first 4-8 weeks, noting energy, temperature regulation, and mood.
• Heart rate: some women feel more sluggish after switching off NDT simply because they miss the T3 effect, not because their labs are out of range.

The reverse switch: from Tirosint to combination

If you have been on Tirosint with optimized TSH and free T4 but still report unacceptable residual symptoms, your clinician may add a low dose of Armour Thyroid, starting at half a grain, rather than switching entirely to NDT. This preserves Tirosint's absorption advantage for the T4 component and adds T3 in a small, titrated amount. Labs should include free T3 to ensure you are not drifting above the upper limit of the reference range, because supraphysiologic free T3 is the marker most associated with atrial fibrillation risk in older studies.

Risks and Cautions Worth Naming Directly

Cardiovascular

The T3 in Armour Thyroid is fast-acting. In women with pre-existing atrial fibrillation, significant coronary artery disease, or established osteoporosis, the daily T3 spike from NDT, including the combination regimen, adds cardiac stress that standard levothyroxine does not. The American Thyroid Association guidelines note that TSH suppression below the lower reference limit is associated with a 2- to 3-fold increased risk of atrial fibrillation. This applies to over-replacement with either NDT or T4, but NDT's T3 makes it easier to overshoot.

Bone mineral density

Post-menopausal women on even mildly suppressed TSH have lower bone mineral density at the femoral neck and lumbar spine compared to those with TSH in the normal range. A Lancet meta-analysis of observational data found that subclinical hyperthyroidism doubled the risk of hip fracture in post-menopausal women. Adding T3 through NDT raises this concern further.

Variability in NDT potency

Natural desiccated thyroid is derived from animal glands. Batch-to-batch variation exists, and patients who are very sensitive to small dose changes, including women in perimenopause whose thyroid needs are already in flux, may notice symptom swings when switching between lots. Tirosint, as a pharmaceutical preparation, does not carry this variability.

Drug interactions

Both drugs interact with calcium supplements, iron supplements, antacids, and PPIs, though Tirosint's liquid formulation reduces the interaction risk. Women taking calcium for bone health, which is most post-menopausal women, should take thyroid medication at least four hours apart from calcium.

Who This Is Right For, and Who It Is Not

May be a reasonable candidate for combination therapy (Tirosint + low-dose Armour)

• You have confirmed Hashimoto's with poor absorption of standard levothyroxine tablets.
• Your TSH is optimized, free T4 is mid-range, but free T3 is consistently in the lower third of the reference range alongside ongoing symptoms.
• You are pre-menopausal, cardiovascularly healthy, with normal bone density.
• You have tried, and discontinued, straight NDT monotherapy because the full-dose T3 caused palpitations, but you felt better on it symptom-wise.

Not a good fit for combination therapy

• You are pregnant or actively trying to conceive.
• You are post-menopausal with osteopenia or osteoporosis.
• You have a history of atrial fibrillation or any tachyarrhythmia.
• Your TSH is already at or below the lower reference limit on current therapy.
• You have a condition causing severe GI malabsorption (in which case, Tirosint alone may be all you need to restore stability).

Evidence Gaps: What We Do Not Know for Women

Women have been enrolled in thyroid trials, which is better than in many therapeutic areas, but several gaps remain. The Hoang 2013 crossover trial included women and men but did not report results stratified by sex or menopausal status. The Vita 2014 Tirosint absorption study focused on autoimmune thyroiditis, a predominantly female condition, but did not assess outcomes by hormonal status or life stage. No published trial has evaluated the Tirosint-plus-Armour combination specifically. Data on DIO2 polymorphism prevalence across reproductive life stages in women are sparse. What clinicians call "combination therapy" is largely built on mechanistic reasoning, patient-preference data from crossover studies, and case-series experience, not on a randomized trial designed for women across menopause.

This is not a reason to dismiss combination therapy. It is a reason to require individualized monitoring rather than treating it as a standard protocol.